Your session is about to expire
← Back to Search
CagriSema for Type 2 Diabetes
Study Summary
This trial will test how well a new medicine called CagriSema helps people with type 2 diabetes to lower their blood sugar and body weight. CagriSema is not yet approved
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
At present, how many distinct locations are simultaneously conducting this experimental investigation?
"This clinical trial is being conducted at various locations, including BSES MG Hospital in Jaipur, J K Lon Hospital and SMS Medical College & Attached Hospitals in Vellore. Additionally, Christian Medical College Hospital in Kolkata is also participating. In total, there are 223 other sites involved in the study."
What are the potential risks and hazards associated with CagriSema in relation to patient safety?
"The safety of CagriSema is rated as 3 based on our assessment at Power. This rating aligns with the Phase 3 nature of the trial, which indicates that there is evidence supporting its effectiveness and multiple rounds of data demonstrating its safety."
Are individuals currently able to enroll in this ongoing medical study?
"The information from clinicaltrials.gov indicates that this study is currently not in the recruitment phase. Although it was initially posted on January 16th, 2024 and last updated on January 15th, 2024, there are presently no openings for participants. However, there are a total of 1388 other ongoing clinical trials actively seeking eligible candidates at this time."
What is the primary objective of conducting this clinical trial?
"Novo Nordisk A/S, the trial sponsor, has identified the primary outcome of this study as the change in glycated haemoglobin (HbA1c) levels. This measurement will be taken from baseline (week 0) to the end of treatment (week 68). The secondary outcomes being assessed include achieving a weight reduction equal to or greater than 5%, changes in systolic blood pressure measured in mmHg, and changes in diastolic blood pressure also measured in mmHg."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger